Kevin Kunzmann

Amantadine previously received FDA approval for antiviral and antiparkinsonian treatment.

Oral anticonvulsant therapy significantly reduces seizure rates compared with phenobarbital.

Patients who undergo lung resection surgery found to become persistent opioid users in the months following their procedure.

Non-invasive nerve stimulation device approved for the treatment of pain associated with migraines in adult patients.

Therapy silences the expression of the mutant gene associated with OPMD, while also restoring normal gene function.

Landmark trial to evaluate the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.

Promacta is a bone marrow stimulant previously approved by the FDA to treat adults and children with chronic immune thrombocytopenia.

Galcanezumab shows efficacy, safety, and tolerability for the preventive treatment of migraines.

The FDA has published an update to its list of off-patent, off-exclusivity drugs without any approved generics.

THC found to slow the process of neurodegeneration, which affects nearly half of all patients with HIV.

Trelegy Ellipta is a combination of an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2-adrenergic agonist for chronic obstructive pulmonary disease.

llergan’s TrueTear Intranasal Tear Neurostimulator was granted marketing authorization by the FDA in April.

Nucala is an interleukin-5 antagonist under consideration as an add-on maintenance therapy for certain patients with chronic obstructive pulmonary disease.

Dupilumab is a monoclonal antibody previously approved to treat moderate-to-severe atopic dermatitis.

The FDA approved 763 generic drugs in the 2017 fiscal year, which is the highest annual rate since the administration began recording the data.

Gocovri is the only FDA-approved therapy for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy.

Soliris treats paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

A novel, oral anti-amyloid optimized prodrug of tramiprosate has a novel mechanism that blocks an agent of Alzheimer’s disease development and progression.

The FDA a stop to Celgene’s REVOLVE trial and extension trial for GED-0301 (mongersen), an oral compound currently not approved for any uses.

Valbenazine (Ingrezza) was the first approved treatment for the antipsychotic medication-induced movement disorder.

The monoclonal antibody dupilumab may be effective treating active moderate-to-severe eosinophilic esophagitis.

Voretigene neparvovec (Luxturna) treats biallelic RPE65-mediated inherited retinal disease.

National brand spending and new patient rates for hepatitis C virus dropped last year.

Qualitative nucleic acid test is designed to detect Zika virus RNA in individual donor plasma specimens.

Two different Copaxone injection doses approved for relapsing forms of multiple sclerosis.

New classes of multiple sclerosis medications are improving on disease suppression.

Obeticholic acid (Ocaliva) for primary biliary cholangitis has been tied to 30 severe liver damage cases.

Altered stem cells are capable of developing into cartilage cells that create a biologic anti-inflammatory drug.